Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pembrolizumab in hormone receptor-positive hypermutated metastatic breast cancer (MUTATION2)
KCT0003274Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in breast cancer, sponsored by Merck & Co.. Planned start Aug 2019; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0003274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003274.